Science
Alzheimer's Drug Lecanemab Shows 27% Cognitive Decline Reduction in Major Clinical Trial
Lecanemab shows 27% reduction in cognitive decline for early Alzheimer's patients. The breakthrough could transform dementia treatment worldwide.
1 article